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MyoﬁbroblastBone marrow transplant experiments in mice using labelled donor bone marrow have indicated that following
injury bone marrow derived cells can circulate and home to the injured organs. In particular ﬁbrocytes and
myoﬁbroblasts are capable of contributing to thewound healing response, including collagen deposition. In chron-
ic injury this can lead to a pathological degree of ﬁbrosis. Experiments have shown that this can be a relatively in-
signiﬁcant contribution to the scar forming population in certain organs and that the majority of the scar forming
cells are intrinsic to the organ. Conversely, in certain circumstances, the circulating cells become major players in
the organs ﬁbrotic response. Whilst cell tracking experiments are relatively simple to perform, to actually deter-
mine a functional contribution to a ﬁbrotic responsemore sophisticated approaches are required. This can include
the use of bone marrow transplantation from recipients with collagen reporter systems which gives a read out of
bone marrow derived cells that are transcriptional active for collagen production in a damaged organ. Another
technique is to use bone marrow transplants from donors that have a mutation in the collagen to demonstrate a
functional difference in ﬁbrosis when bone marrow transplants performed. Recent reports have identiﬁed factors
mediating recruitment of circulating ﬁbrocytes to injured organs, such as CXCL12 and CXCL16 and shown that
blocking these factors reduced ﬁbrocyte recruitment and subsequent ﬁbrosis. The identiﬁcation of such factors
may enable the development of novel therapies to block further ﬁbrocyte engraftment and ﬁbrosis in situations
of pathological scarring. This article is part of a Special Issue entitled: Fibrosis: Translation of basic research to
human disease.
© 2013 Published by Elsevier B.V.1. General considerations—what techniques are used to assess the
evidence for the bone marrow (BM) contributing to organ ﬁbrosis?
In this section we will discuss the evidence for BM derived cells
contributing to organ ﬁbrosis. To understand the techniques that have
been used to assess contribution of BM derived cells to ﬁbrogenesis in
injured organs it is worth brieﬂy reviewing the stem cell composition
of the BM.
2. The composition of the BM
2.1. The haematopoietic stem cells
The haematopoietic stem cells (HSCs) residing within the BM
are multipotent and are the source of the myeloid and lymphoid
populations of the blood. Haematopoietic stem cells are radiationreatitis; (EOG-EPC)s, early outgrow
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netically marked BM such as green ﬂuorescent protein (GFP) labelled
BM, sex-chromosome markers (where the recipient mice are female,
XX and the donorsmale, XY) or other technologies. The donor haemato-
poietic stem cells can be puriﬁed and sorted with speciﬁc markers,
following peripheral vein injection are able to engraft the irradiated re-
cipients BM and then differentiate into the progeny of haematopoietic
stem cells providing long term repopulation of all the blood lineages.
The application of known doses of irradiation can produce recipient
BMwhere practically all of the haematopoietic system is of donor origin
and this can be easily checked using FACS (e.g. for GFP). Analysis of the
engraftment and functional effects of the progeny of haematopoietic
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Fibrocytes are inactive precursors of the collagen secreting ﬁbro-
blasts. Circulating ﬁbrocytes have been identiﬁed in the blood that are
CD34+, CD45+, collagen-1+. These ﬁbrocytes are thought to be able
to circulate in the blood, differentiate into ﬁbroblasts and contribute
to collagen accumulation in injured organs [1]. Fibrocytes have been
implicated in ﬁbrogenesis in the skin, lung, liver and kidney and are
characterised as expressing haematopoietic markers (CD11b, GR1,
CD45) as well as markers of cell adhesion (CD54) and co-stimulatory
molecules CD80 and CD86 and secrete pro-ﬁbrotic cytokines and
growth factors (TGF-b and MCP-1). Fibrocytes are recruited to injured
organs via a variety of cytokines and chemokines and recruitment can
be inhibited in mice deﬁcient in chemokine receptors particularly
CCR2, CXCR4 and CCR5 in the lung [2,3] and CCR2, CCR7 and CXCR4 in
the kidney [4]. Human serumamyloid protein (hSAP) is a natural inhib-
itor of ﬁbrocyte differentiation and maturation [5]. Mice treated with
hSAP develop less ﬁbrosis in response to injury in several organs and
have been successfully tested in limited clinical trials in patients with
skin, kidney and lung ﬁbrosis [6–10], suggesting an important role for
these cells in pan-organ ﬁbrosis.
2.3. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are capable of tri-lineage differ-
entiation into osteoblasts, chondrocytes, and adipocytes [11]. MSCs
are classiﬁed by the expression of mesenchymal markers CD105,
CD90 and CD73, and lack of expression of haematopoietic markers
CD45, CD34, CD14 and CD11b and are thus distinct from ﬁbrocytes
which express CD45 and CD11b. As well as their regeneration effects,
MSCs are also thought to modulate disease progression via their
anti-inﬂammatory and immune-modulatory properties and secrete
a variety of mediators such as TGF-β, IL-10, prostaglandins and
indolamine 2, 3-dioxegenase and support the development of regula-
tory T cells [11–15]. In addition the effects and functional properties
of MSCs may be inﬂuenced by the inﬂammatory milieu and can
adopt a pro-inﬂammatory MSC1 and anti-inﬂammatory MSC2 pheno-
type, similar to that adopted by macrophages [16]. Several studies
have reported that MSCs from patients exhibit a completely recipient
proﬁle after total body irradiation and BM transplantation, whereas
HSCs are of donor origin [17,18] suggesting that MSCs in their niches
are likely to be radio-resistant. Furthermore in the experimental set-
ting, when using standard irradiation and BM transplant procedures
in mice and rats, the resident promising population is unaffected by
irradiation, unlike the HSC population which becomes of donor origin.
Therefore it is not straightforward to determine whether MSCs contrib-
ute to organ ﬁbrosis in disease states. It is worth considering their
ﬁbrogenic potential either in disease, or perhaps of more relevance,
following the injection of exogenous MSCs as these cells are being con-
sidered for use in cell therapies in a number of diseases. The ability to
isolate and expand human MSCs in culture has stimulated research
into their therapeutic potential where MSCs have been expanded in
culture and injected during injury models. For example MSCs have
been shown to reduce ﬁbrosis and tubular atrophy in a rat kidney allo-
graftmodel [19] and have beneﬁcial effect inmyocardial infarction, lung
ﬁbrosis and acute liver injury [20–22]. Thus MSCs may have potential
clinical use in certain disease scenarios. The factors regulating the
mobilisation of MSCs from the BM are less well understood than those
factors governing HSC mobilisation. While GCSF stimulates MSC prolif-
eration in the BM it does not stimulate mobilisation and a combination
of the CXCR4 antagonist AMD3100 (which effectively mobilises HSCs)
with GCSF did not mobilise MSCs [23] However, stromal progenitor
cells have been mobilised from the BM in mice using a combination of
CXCR4 and VEGF [23]. MSCs are currently being evaluated in several
clinical trials for a variety of diseases, including Crohn's disease, multi-
ple sclerosis, diabetes mellitus, and acute graft-vs-host disease, withsome efﬁcacy [11,24–26] but their use in ﬁbrotic disease remains to
be established.
3. Endothelial progenitor cells (EPCs)
EPCs are a population of mononuclear cells in the blood thought to
be capable of differentiating into endothelial cells in vitro. These cells
are suggested to contribute to angiogenesis either by directly differ-
entiating into endothelial cells or by secreting proangiogenic factors
and chemokines such as VEGF, CXCL12 and IGF-1 [27]. EPCs are cul-
tured from blood mononuclear cells and form colonies in the presence
of endothelial growth factors. Early outgrowth EPCs (EOG-EPC)s have
characteristics of both endothelial and monocytic cells and express
CD45, CD11c, and CD14, and the endothelial markers CD31 and
VEGFreceptor-2. Late outgrowth EPCs (LOG-EPC)s express the endothe-
lial markers and CD34 but do not express monocytic markers. The po-
tential for EPC transplantation and therapy has been most widely
studied in cardiovascular disease where transplantation of EPCs has
been shown to reduce ﬁbrosis in several models e.g. myocardial infarc-
tion [28]. However EPCs have also been shown to reverse liver ﬁbrosis
[29] and reduce portal hypertension associated with CCl4-induced
liver cirrhosis [30] and reduce obstructive renal ﬁbrosis [31].
3.1. Tracking BM cells in human tissue
In humans, to determine the presence of BM derived cells in
injured organs it has been necessary to analyse tissue from patients
that have received BM transplants. Typically this has been female (XX
chromosomes) patients that have received male (XY chromosomes)
BM transplants where the Y chromosome denotes a human cell that
can be tracked in a damaged organ using in situ hybridisation for the
Y chromosome. This can be combined with immunohistochemistry for
a cell type marker (e.g. such as αSMA to mark a myoﬁbroblast) to
conﬁrm cell phenotype [32]. However, the combination of standard in
situ hybridisationwith immunohistochemistry analysis may not be suf-
ﬁcient to localise the nuclear Y chromosome in the nucleus with αSMA
expression in the cytoplasm in individual cells [33]. Other approaches
have involved analysing female organs that have been transplanted
into male recipients for evidence of male (recipient) myoﬁbroblasts in
the organ, although this does not directly prove BM origin. These histo-
logical studies have been useful for suggesting a potential role of the
BM in organ ﬁbrosis but are of course descriptive and not functional.
Furthermore, techniques such as in situ hybridization can be difﬁcult
to optimise and also need rigorous analysis with appropriate controls
to prevent inappropriate conclusions being reached.
3.2. Evidence that the BM cells are synthesising and secreting collagen
The evidence that BM cells are synthesising collagen can be obtained
using transgenic mice that are transcriptional reactive for collagen or
express a ﬂuorescent gene under the control of a speciﬁc promoter
such as a collagen or αSMA gene [34,35]. However it is worth noting
on a technical level that if one uses collagen reporter mice, this will
show transcriptional activity at the time of assay (typically when tissue
is harvested unless whole body live imaging is used). This may miss an
earlier burst of transcriptional activity, furthermore collagen gene tran-
scription is only part of the process required to actually deposit collagen
in tissue. Another way of determining transcriptional activity for colla-
gen is to look for RNA using collagen ribo-probes in cells that can be
detected in tissue sections [36]. Using these approaches it has been
shown that a small proportion of BM derived myoﬁbroblasts in the
liver are transcriptionally active for collagen. Another approach has
used in vivo imaging to track collagen expressing ﬁbrocytes to the
liver using BM from chimeric mice expressing luciferase under control
of the α1(I) collagen promoter [37]. Another study used BM transplan-
tation from donor mice with a genetic mutation of the collagen gene.
Table 1
Reported levels of ﬁbrocytes and EPCs in human ﬁbrotic disease.
Fibrocytes
Normal 0.5% circulating leukocytes [43]
IPF 20% circulating leukocytes [43]
Asthma 3 fold increase compared to control [83]
Scleroderma 2 fold increase compared to control [9]
Hepatitis C Up to50% circulating leukocytes [84]
Decompensated cirrhosis Up to 23.3% circulating leukocytes [84]
EPCs
COPD 40–60% increase [85]
Cirrhosis Increased from 0.01 to 0.1% leukocytes [86]
IPF 7% of total lung cells [87]
Asthma 1.7 fold increase circulating EPCs [88]
The actual ﬁgures should be treated with caution and are not directly comparable as
different methodologies are employed by individual groups.
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BM-derived cells secrete collagen and could contribute to ﬁbrosis [36].
Furthermore, using dual immunoﬂuorescence, collagen expressing
ﬁbrocytes can be easily discriminated from resident ﬁbroblasts in
human ﬁbrotic lung [38].
3.3. Organ speciﬁc considerations of the BMs inﬂuence upon organ ﬁbrosis
3.3.1. Lung disease
In allergic asthma in humans a population of cells were identiﬁed
by Schmidt et al. as being ﬁbrocytes (collagen I, CD34+); the authors
went on to perform BM tracking experiments in a mouse model of
allergic asthma and identiﬁed ﬁbrocytes that were engrafting the
lung from a circulating population. Furthermore, they were able to
show in vitro that human circulating ﬁbrocytes differentiated into a
ﬁbroblasts phenotype (αSMA+) in the presence of inﬂammatory
cytokines [32,39]. In a murine model of obliterative bronchiolitis
using heterotopic tracheal transplantation, circulating ﬁbrocytes
(CD45+, CXCR4+, collagen I+) engrafted the tracheal allograft and
differentiated into ﬁbroblasts. Through the use of an antibody to
block the CXCL12 mediated ﬁbrocyte migration a functional beneﬁt
was seen with less luminal obliteration and collagen deposition
[40]. Fibrocytes have also been shown to trafﬁc to the lungs following
bleomycin challenge; both human ﬁbrocytes in SCID mice and mouse
ﬁbrocytes in immune-competent mice [2,41]. Using BM transplant of
GFP+ cells into WT mice CD45+/Col1+ GFP+ cells were found in
the lungs following bleomycin challenge [2,41]. However Hashimoto
and colleagues found no evidence that these cells differentiated into
myoﬁbroblasts and synthesised α-SMA. This may be due to incom-
plete repopulation of the BM following irradiation and transplant as
a recent study showed that a small population of GFP− ﬁbrocytes
remained in the BM following lethal irradiation and transplant [42].
In ﬁbrotic lung disease, the number of accumulating ﬁbrocytes
may be as much as 25% [42] and may signiﬁcantly contribute to
pulmonary ﬁbrosis. Inhibition of the chemokine CXCl12 with a
neutralising antibody reduced ﬁbrocyte recruitment and lung ﬁbrosis
following bleomycin [2]. Moreover, elevated levels of circulating
ﬁbrocytes in peripheral blood in patients with idiopathic pulmonary
ﬁbrosis (IPF) correlate with poor prognosis [43] and are increased
during acute exacerbations of the disease, whilst there was no eleva-
tion in ﬁbrocyte numbers in patients with acute respiratory distress
syndrome (ARDS) suggesting a speciﬁc role for these cells in idio-
pathic pulmonary ﬁbrosis IPF [43] (Table 1). MSCs have been shown
to home to the lung in response to ﬁbrotic injury with bleomycin,
and reduce inﬂammation and myoﬁbroblast activation [21]. Whilst
some studies show that these cells can incorporate into the airway
epithelium and contribute to repair, other studies using a transgenic
reporter mouse expressing GFP only in alveolar epithelial cells
(surfactant protein C-GFP) argue against this being the case [44].
However, the injection of human umbilical vein MSCs has been
shown to reduce ﬁbrosis following bleomycin [45]. The role of MSCs
and the potential for MSCs cell therapy in lung ﬁbrosis therefore
require further study.
3.3.2. Kidney ﬁbrosis
Whilst the majority of scar forming cells in the kidney appeared to
derive from endogenous pericytes [46], there also appears to be some
contribution to ﬁbrosis from circulating BM drive cells. Dual CD45+/
type 1 collagen+ cells have been detected in the corticomedullary
regions in ureteral ligationmodel of kidney ﬁbrosis inmice [4]. Further-
more ﬁbrocytes have been detected in human kidneys, CD45+/
proCol1+ cells were seen in kidneys of patients with diabetic nephrop-
athy and the numbers of cells in the interstitium correlated with the
severity of tubulointerstitial lesions including interstitial ﬁbrosis [47].
The functional signiﬁcance of this route of ﬁbrosis has been
demonstrated using CXCL 16-knockout mice in a unilateral ureteralligation model of renal ﬁbrosis. Investigators found that compared
with wild-type mice, CXCL16-knockout mice had signiﬁcantly fewer
BM-derived ﬁbroblast precursors, together with fewer CD45-, collagen
I-, and CXCR6-triple-positive ﬁbroblast precursors in injured kidneys.
This resulted in less renal myoﬁbroblast activation and collagen deposi-
tion [48].
3.4. Liver ﬁbrosis
Using BM transplantation from GFP positive donor mice into wild
type recipients Baba et al. found that a proportion of stellate cells in
the recipients liver were marked with the GFP transgene, suggesting
that stellate cells may have the potential origin from BM [49]. Other
investigators have also suggested in mice models of BM transplant
with subsequent liver injury that both stellate cells and activated
myoﬁbroblasts may, at least in part, have a BM origin [36]. However
other studies have suggested that hepatic stellate cells do not origi-
nate from the BM, and that the BM only contributes to a small number
of collagen expressing cells in the liver following CCl4 injury or fol-
lowing bile duct ligation in mice [35]. Using BM transplant from a
collagen-alpha1(I)–luciferase (Col-Luc) transgenic mouse (which ex-
presses which luciferase under the control of the collagen-alpha1(I)
promoter) transplanted into lethally irradiated WT mice, it was
shown that luciferase positive ﬁbrocytes were recruited to the liver
following CCL4 induced liver injury [34]. Another study showed that
BM-derived ﬁbrocytes were recruited to the liver and differentiated
into myoﬁbroblasts an effect that was dependent on CCR1 [37]. Fur-
thermore the investigators found little evidence of BM derived cells
actually contributing to collagen transcription in the liver injury
models. These contradictory results are certainly worthy of further
investigation and in particular it may be worthy examining closely
the role of the BM stromal cell population for the reasons outlined
earlier as their contribution to any pro-ﬁbrotic response may not
read out in conventional adoptive transplant experiments.
In humans there has been a suggestion that a modest proportion
(approximately 12%) of the myoﬁbroblast like cells in the liver may
have BM origin. This work was performed in two settings: (1) in male
patients that had received female liver transplantation and then, to
had biopsies for recurrent ﬁbrosis; this suggested that a proportion of
themyoﬁbroblasts weremarkedwith the liver recipients chromosomal
markers (Y chromosome positive); this clearly did not prove BM origin
but suggested a potential circulating source. Furthermore female pa-
tients have been analysed who have received male BM transplantation
and then go on to develop liver injury; and again in this setting a
proportion of themyoﬁbroblasts contain the Y chromosome suggesting
potential BM origin [32].
Towards the development of a potential cell therapy for liver
ﬁbrosis it was reported that transplantation of whole BMCs [50] and
MSCs [51] reduces CCl4-induced liver ﬁbrosis in mice with decreased
collagen production and increased MMP13 levels [51]. However
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no anti-ﬁbrotic effect from MSC injection in models of liver ﬁbrosis
[52]. Furthermore MSCs themselves have been shown to adopt a
myoﬁbroblast phenotype in the liver. Di Bonzo et al. have shown that
the injection of human MSCs into an immunodeﬁcient mouse with
liver injury resulted in the MSCs engrafting the liver and adopting a
myoﬁbroblast phenotype [53]. In addition another study has demon-
strated whole BM to be pro-ﬁbrotic following portal vein injection
inmice, whereas puriﬁed fractions of BMderivedmacrophages resulted
in a signiﬁcant reduction the liver ﬁbrosis [54]. However, a recent study
has also shown that injection of autologous cultured bone marrow
cells (comprising a mixture of macrophages and mesenchymal cells)
improved liver function and liver ﬁbrosis in mice [55]. Therefore, the
speciﬁc bone marrow compartments contributing to reduced liver
ﬁbrosis after injection and therefore with potential as a therapy is still
under debate. Clinical studies have reported improved liver function
in cirrhotic patients following autologous bone marrow cell infusion
therapy [56] and following infusion with umbilical cord MSCs [57,58],
although these were not randomised controlled trials. Multicentre clin-
ical trials are now underway and should inform this area in the near fu-
ture [59] (Fig. 1).
3.5. Pancreatic ﬁbrosis
Pancreatic ﬁbrosis is a prominent feature of chronic pancreatitis (CP)
and pancreatic cancer involving activated pancreatic stellate cells. Using
irradiation and transplant of BM constitutively expressing enhanced
green ﬂuorescent protein (EGFP), one study showed that BM-derived
cells accounted for 20.2% of α-smooth muscle actin-positive activated
PSCs following induction of CP by repeated cerulein injections [60]. A
second study in a mouse dietary model of pancreatitis revealed that
the number of BM-derived activated pancreatic stellate cells rose
during injury to 23.3±0.9% of all activated pancreatic stellate cells
which produced PDGF and TGFβ1 [61]. Interestingly the proportion of
BM-derived cells then fell as the injury resolved. With reference to
human tissue, Barth and co-workers showed that CD34+ ﬁbrocytes
and myoﬁbroblasts could be detected in human chronic pancreatitis
and ductal adenocarcinoma [62].
3.6. Skin ﬁbrosis
There are a number of reports in mice suggesting that BM derived
cells can engraft skin and produce cells of a ﬁbroblast or myoﬁbroblast
phenotype [63]. However when the actual source of collagen produc-
tion in skin was analysed in a mouse model of ﬁbrogenesis and
wound healing, using mice transplanted with a BM from EGFP-Col1
reporter mice, very little collagen transcription from the BM derived
cells was shown to occur in the skin following dermal excision although
a small number of CD45+/Col1+cells (possiblyﬁbrocytes)were found
after subcutaneous injection of bleomycin [64]. Furthermore BM trans-
plant experiments and parabiosis experiments using a collagen reporter
GFP found no evidence of collagen producing BM derived cells in
skin wounds with all GFP+ cells comprising inﬂammatory cells [65].
However there is mounting evidence that CD45+/Col1+ cells may
contribute to ﬁbrosis in nephrogenic ﬁbrosing dermopathy [66–68]
and following radiation [69].
3.6.1. Gut
Irradiation and BM transplant studies in mice have revealed that a
proportion of the pericryptal myoﬁbroblasts detected in the gut are
derived from the BM. Using in situ hybridisation for the Y chromosome
in female mice that have received irradiation, and transplant with male
BM, frequent Y chromosome positive myoﬁbroblasts were detected
[70]. A follow on study of colitis conﬁrmed that the BM cells were con-
ﬁned to the non-epithelial compartment and did not result in intestinal
epithelial engraftment [71].3.6.2. BM derived monocyte–macrophages
The BM derived macrophages have been shown to inﬂuence both
the development and the recovery of ﬁbrosis in several organs includ-
ing the liver and lung. Murine models of carbon tetrachloride induced
liver injury have been used to analyse the monocyte macrophages
role in liver ﬁbrosis. Using the CD11b-DTR mouse (which expresses
the human diphtheria toxin receptor in cells of myeloid lineage) to
conditionally delete macrophages it was shown that deletion of
macrophages during hepatic injury reduced the formation of liver
ﬁbrosis; however deletion of macrophages during the recovery phase
from the liver injury resulted in less resolution of the liver ﬁbrosis [72].
Using BM cell tracking by sex mismatched BM transplantation it was
shown that nearly half of the scar associated macrophages in the liver
were indeed circulating from the BM [72]. The fact that macrophages
may have an anti-ﬁbrotic role in liver ﬁbrosis has been exploited to
develop macrophages as a cell therapy for liver ﬁbrosis. Thomas and
co-workers showed that a single intra-portal injection of macrophages
was able to have a signiﬁcant effect on the ﬁbrosis and regeneration
in the CCl4 model of chronic injury [54]. The macrophage injection
had a profound effect upon the cell milieu in the hepatic scar area and
induced recruitment of endogenous macrophages and neutrophils to
the scar area. This cellular inﬂux stimulated a regulation of matrix
metalloproteinase that was able to induce apoptosis of hepatic my
ﬁbroblasts together with a reduction in hepatic collagen. Alongside
this, macrophage injection induced a stimulation of the regenerative
response in the damaged liver.
The function of macrophages in the progression of pulmonary
ﬁbrosis has been under debate for several years primarily due to the
ﬁnding that human IPF is largely unresponsive to corticosteroids. How-
ever, recent published data suggest that this situation may be more
complex than previously thought [73]. Using the bleomycin model
it has been shown that lung macrophages can be the predominant
source of TGF-β in the lung [74]. Furthermore, corticosteroids have
been shown to support alternative macrophage activation and increase
secretion of TGF-β [75]. Moreover, a recent study in patients whodevel-
op an accelerated form of ﬁbrotic lung disease demonstrated that they
have deregulated alveolar macrophages [76]. Gibbons and co-workers
showed that alternatively activated macrophage expansion was stimu-
lated by recruited Ly6Chi monocytes and could exacerbate ﬁbrosis in-
duced by bleomycin and adenoviral delivery of TGF in the mouse lung.
Moreover, ablation of lung macrophages during ﬁbrogenesis reduced
the resulting lung ﬁbrosis in these models [73]. This demonstrates a
crucial role for macrophages in determining the severity of ﬁbrotic
lung injury and opens a novel area of investigation to identify new
therapies to treat patients with IPF.
4. BM cells in the ﬁbrotic response to cancers
BM cells particularly MSCs also contribute to the development of
new tissue stroma and this has been widely studied in wound repair
and in the lung; however tumour formation is also uniquely dependent
on the surrounding stromal cells of the tumour microenvironment.
The stroma contains resident structural cells (ﬁbroblasts, epithelium
and endothelium) and inﬂammatory cells which secrete growth factors
that function to protect the developing tumour from immune attack.
BM transplant experiments have shown that up to 40% of the
myoﬁbroblasts are BM-derived inmurine studies [77]. There is an abun-
dance of literature showing thatMSCs speciﬁcally home to and incorpo-
rate into the tumour stroma in several malignancies including breast,
lung and colorectal cancer (reviewed in Ref. [78]). However their func-
tion within the stroma is unclear. On one hand MSCs have been shown
to be tumorigenic as they form the protective stroma and are anti-
inﬂammatory and produce factors such as VEGF, TGF and IL-10 and
indolamine dioxygenase which down regulate T cell function and pro-
mote angiogenesis. However there is also evidence that they can have
anti-tumorigenic effects by down regulation of the wnt and Akt
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Fig. 1. Bone marrow cells involved in organ ﬁbrosis and potential therapy.
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is the use of MSCs as delivery vehicles for chemotherapy or cytotoxic
drugs [79,81,82]. Exogenously delivered MSCs are a particularly attrac-
tive avenue for stem cell mediated cancer therapy, as unlike HSCs
they can be given as cellular therapy as they can be rapidly expanded
in vitro and do not pose the potential problems associated with
irradiation and BM transplantation as they lack expression of MHC-II
and co-stimulatory molecules. Approaches here have included MSCs
expressing the apoptosis inducing TRAIL and IFNs [81].
5. Conclusions
The BM contribution to organ ﬁbrosis is a particularly controversial
area with many contradictory results using varying methodologies in
different models. This makes broad conclusions particularly difﬁcult;
however, some can be drawn. There are a population of circulating
ﬁbrocytes that can engraft certain organs in conditions of inﬂammation
and tissue damage and these cells are a likely source of collagen to some
degree. Blocking their recruitment appears to have therapeutic beneﬁt
particularly in the setting of lung ﬁbrosis. MSCs remain enigmatic de-
spite years of study; there are many published results showing that
their use in model of organ injury and ﬁbrosis can resource injury, in-
ﬂammation and ﬁbrosis. Yet there are many negative studies also and
even studies showing that the injected MSCS can adopt a scar forming
phenotype. It will be worth considering whether their therapeutic use
is justiﬁed based upon the organ, context, and chronicity of the injury
and the experimental evidence available. Modern mouse transgenic
technologies using collagen reports systems are bringing clarity to the
ﬁeld and have revealed that in certain settings there is little apparent
collagen deposition from the BM in these models (e.g. skin). This ﬁeld
will grow and bring greater clarity to the ﬁeld. The BM derived macro-
phages are important orchestrators of the ﬁbrotic response and may
have both pro and anti-ﬁbrotic properties. BM derived macrophages
may also have therapeutic role in organ ﬁbrosis and should be studied
further.
Within the BM there are population of stem cells including MSCs
and HSCs. The progeny of HSCs including ﬁbrocytes and monocytes can
inﬁltrate inﬂamed organs and contribute to ﬁbrosis either directly
(ﬁbrocytes) or through paracrine signalling to other scar forming cells
locally (monocytes and their differentiated formmacrophages). Stromal
progenitor cells may mobilise from the BM in certain conditions. In therecovery from injury and ﬁbrosis macrophages can orchestrate and
directly aid the resolution of ﬁbrosis. MSCs can have anti-inﬂammatory
and anti-ﬁbrotic effects in some models of organ ﬁbrosis; however
they may directly from myoﬁbroblast-like cells also. Macrophages may
have some therapeutic potential in cell therapy.
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